Pediatric Exclusivity 90-Day Review Can Be “Difficult” Target – Kweder
Executive Summary
FDA sometimes is challenged to meet the deadline for completing the review of whether a drug sponsor's clinical trials in children qualify a product for pediatric exclusivity, Office of New Drugs Deputy Director Sandra Kweder indicated May 22
You may also be interested in...
Pediatric Exclusivity Breaks 3-Month Cap In House, But Still Must Find Offset
The legislation to renew the pediatric exclusivity language in the House now provides six months for all products as opposed to the sales-tiered incentives in the Senate bill, but the more generous offer serves to underline the challenge to the program - finding an offset to pay for it
Pediatric Exclusivity Breaks 3-Month Cap In House, But Still Must Find Offset
The legislation to renew the pediatric exclusivity language in the House now provides six months for all products as opposed to the sales-tiered incentives in the Senate bill, but the more generous offer serves to underline the challenge to the program - finding an offset to pay for it
FDA Reform Bill Leaves Senate With Reduced Safety Powers But Stiffer Fines
Legislation to reauthorize FDA's user fee program and expand the agency's oversight powers on drug safety has cleared the Senate with much stronger fines than originally envisioned by the sponsors, thanks to an amendment by Sen. Charles Grassley, R-Iowa